Autor :David Peña 1-2
1 Pulmonologist graduated from UBA, recertified, AAMR
2International Master Degree in Pulmonary Hypertension
Chronic
obstructive pulmonary disease (COPD) is a multisystem disease whose morbidity
and mortality are undoubtedly related to its associated chronic comorbidities,
to a greater extent in those who do not suffer from it, with these
comorbidities often being the cause of death.
The
management of patients with COPD, must include a set of factors that
significantly influence the prognosis and number of hospitalizations, such as
advanced age, FEV1 value, the degree of dyspnea measured by the MRC (Medical
Research Council) Scale, the number of exacerbations per year, the level of pO2, and
the degree of functional dependence. Likewise, these patients have a higher
prevalence of cardiovascular diseases, cancer, and depression than the general
population, among other comorbidities.
Although
we do not have a single tool that enÂcompasses everything mentioned, it is
useful to use different indices that allow for a better assessment of these
patients. The Charlson Index, which is not specific to COPD, groups many of the
comorbidiÂties and expresses life expectancy in terms of 10 years, taking into
account some not included but prevalent comorbidities such as arterial hypertenÂsion,
osteoporosis, abdominal obesity, dyslipidemia, anemia, depression, and anxiety.
Similarly, it is important to note that this population presents a higher
frequency of ischemic heart disease, myoÂcardial infarction, and chronic renal
failure.
The
BODE Index (body-mass index, airflow obstruction, dyspnea, and exercise
capacity), which is easy to calculate and shows a strong corÂrelation with
survival, was initially designed to replace the FEV1 as the sole predictor of
COPD patient evolution and is extremely useful. The ADO (Age, Dyspnea, Airflow
Obstruction) Index is also very useful. It is multidimensional and has good
correlation with quality of life measured by the EQ-5D and Visual Analogue
Scale (VAS), like the BODE Index.
For
assessing the degree of independence in relation to activities of daily living,
the Katz InÂdex is useful, and it is also helpful in evaluating quality of
life.
In
this issue, an article is published on the coÂmorbidities of COPD and their
impact on morbidÂity and mortality. (1) It correlates the severity
of COPD, the COTE index, and mortality but does not find a correlation between
the variables under consideration and mortality. The study of Jiménez
and Sívori published in this review last year comÂpared the Charlson and
COTE indices in COPD and its relationship with mortality. The correlation
between both indices was found to be poor, with the Charlson Index being better
at discriminating mortality. (2)
Therefore,
studying comorbidities in COPD is essential in the management of these
patients, and interdisciplinary care should be provided. SimilarÂly, the
systematic use of multidimensional indices is important to allow for a better
assessment of comorbidities and their impact on mortality. These indices are
valuable not only for their prognostic value but also to enable timely
intervention in the various areas that may require it.
REFERENCES
1.
Abrate V, Ubal LG, Fernández JN, Elías MA, Olmos ME, Cesaratto F,
et al. Comorbidities in COPD and their impact on morbidity and mortality after
a 5-year follow up. Rev Am Med Resp 2023;23:75-83
2.
Jiménez JJ, Sívori M. Comparación de los índices de
CharlÂson y COTE en la enfermedad pulmonar obstructiva crónica (EPOC) y
su relación con la mortalidad. Rev Am Med Resp 2022;1:3-9.